Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Acadia Pharmaceuticals Inc's Business Segments
Acadia Pharmaceuticals Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reportable Segment Aggregation Before Other Operating Segment
Total Revenue
$ 268
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reportable Segment Aggregation Before Other Operating Segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable Segment Aggregation Before Other Operating Segment | $ 268 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- NUPLAZID62.3%
- DAYBUE37.7%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| NUPLAZID | $ 167 | 62.3% |
| DAYBUE | $ 101 | 37.7% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Acadia Pharmaceuticals Inc
Acadia Pharmaceuticals Inc is a publicly traded biopharmaceutical company, founded in 1997 in San Diego, California, USA. The company's primary focus is on developing and commercializing drugs that address unmet medical needs in central nervous system (CNS) disorders, such as Parkinson's disease, Alzheimer's disease, schizophrenia, and depression.
Acadia's flagship drug is pimavanserin, which is marketed as Nuplazid. It is the first and only FDA-approved treatment for Parkinson's disease psychosis, a condition that affects up to 50% of Parkinson's disease patients. Pimavanserin selectively targets serotonin 5-HT2A receptors, which are believed to contribute to the hallucinations and delusions experienced by these patients. Nuplazid was approved by the FDA in 2016, and it has since been prescribed to over 200,000 patients.
Acadia also has a pipeline of other CNS drugs in various stages of development. Its product candidates include:
- Trofinetide: A potential treatment for Rett syndrome, a rare genetic disorder that affects mainly girls and causes developmental and cognitive disabilities.
- ACP-044: A potential treatment for schizophrenia and other psychiatric disorders.
- ACP-319: A potential treatment for major depressive disorder and other mood disorders.
- ACP-105: A potential treatment for Alzheimer's disease and other neurodegenerative disorders.
Acadia has partnerships with several pharmaceutical companies, including Eisai, AstraZeneca, and Neuren Pharmaceuticals, to further develop and commercialize some of its products.
Acadia has experienced significant growth in recent years, with a market capitalization of over $5 billion and a workforce of over 1,300 employees. It has received numerous awards and recognitions for its research and development efforts, including being named one of the World's Most Innovative Companies by Forbes in 2014 and receiving the Prix Galien USA award for Best Biotechnology Product in 201
In addition to its focus on developing innovative CNS drugs, Acadia also prioritizes corporate social responsibility and sustainability. It has implemented various programs to reduce its environmental impact, support local communities, and promote diversity and inclusion within its workforce.
Acadia's flagship drug is pimavanserin, which is marketed as Nuplazid. It is the first and only FDA-approved treatment for Parkinson's disease psychosis, a condition that affects up to 50% of Parkinson's disease patients. Pimavanserin selectively targets serotonin 5-HT2A receptors, which are believed to contribute to the hallucinations and delusions experienced by these patients. Nuplazid was approved by the FDA in 2016, and it has since been prescribed to over 200,000 patients.
Acadia also has a pipeline of other CNS drugs in various stages of development. Its product candidates include:
- Trofinetide: A potential treatment for Rett syndrome, a rare genetic disorder that affects mainly girls and causes developmental and cognitive disabilities.
- ACP-044: A potential treatment for schizophrenia and other psychiatric disorders.
- ACP-319: A potential treatment for major depressive disorder and other mood disorders.
- ACP-105: A potential treatment for Alzheimer's disease and other neurodegenerative disorders.
Acadia has partnerships with several pharmaceutical companies, including Eisai, AstraZeneca, and Neuren Pharmaceuticals, to further develop and commercialize some of its products.
Acadia has experienced significant growth in recent years, with a market capitalization of over $5 billion and a workforce of over 1,300 employees. It has received numerous awards and recognitions for its research and development efforts, including being named one of the World's Most Innovative Companies by Forbes in 2014 and receiving the Prix Galien USA award for Best Biotechnology Product in 201
In addition to its focus on developing innovative CNS drugs, Acadia also prioritizes corporate social responsibility and sustainability. It has implemented various programs to reduce its environmental impact, support local communities, and promote diversity and inclusion within its workforce.
Acadia Pharmaceuticals Inc. is a prominent biopharmaceutical company that specializes in the development and commercialization of innovative therapies for central nervous system (CNS) disorders. The companys focus primarily centers around addressing the unmet medical needs related to neurological and psychiatric conditions through its dedicated segments, products, and services.
Segments:
1. Commercialization:
This segment is critical to the companys operations, as it encompasses all sales and marketing activities, including the promotion and distribution of Acadias flagship product, NUPLAZID. The commercialization team is responsible for building relationships with healthcare providers, payers, and patients to ensure that NUPLAZID is accessible to those in need. The team also manages ongoing marketing efforts and promotional campaigns to raise awareness of the product and educate stakeholders on its benefits.
2. Research and Development (R&D):
The R&D segment is a cornerstone of Acadia Pharmaceuticals’ mission. This segment is devoted to the comprehensive investigation and development of new therapies that target specific neurological and psychiatric disorders. The R&D team employs state-of-the-art techniques and methodologies to explore novel drug candidates, conduct preclinical studies, and execute clinical trials. Their research aims to understand the underlying mechanisms of various CNS disorders, allowing for the development of innovative treatments that provide relief to patients.
Products:
1. NUPLAZID:
NUPLAZID (pimavanserin) stands as Acadias flagship product and the first FDA-approved treatment specifically for Parkinson’s Disease Psychosis (PDP), receiving approval in April 2016. NUPLAZID is a selective serotonin inverse agonist that predominantly targets the 5-HT2A receptors in the brain, contributing to a significant reduction in hallucinations and delusions associated with PDP. The drug is noted for its efficacy and has undergone rigorous clinical trials that demonstrated its safety profile and effectiveness in managing symptoms of psychosis without exacerbating motor symptoms of Parkinsons disease.
Services:
1. Patient Support:
Acadia Pharmaceuticals offers extensive patient support services designed to assist individuals diagnosed with Parkinson’s Disease Psychosis. The patient support team provides educational resources, tools, and counseling to help patients effectively manage their condition. They also offer guidance on the correct administration of NUPLAZID to enhance compliance and ensure optimum therapeutic outcomes.
2. Educational Programs:
The company is committed to enhancing public and professional understanding of CNS disorders through a range of educational programs. These initiatives aim to increase awareness of Parkinson’s Disease Psychosis and its impact, covering the importance of proper diagnosis, treatment options, and support mechanisms available for patients and caregivers.
3. Medical Information:
Acadia Pharmaceuticals maintains a robust medical information service that is available to address inquiries regarding NUPLAZID and other therapeutic options. This service is designed to provide healthcare professionals and patients with timely and scientifically accurate information, helping them make informed decisions related to treatment.
4. Patient Advocacy:
Acadia Pharmaceuticals actively collaborates with patient advocacy organizations to support those living with Parkinson’s Disease Psychosis. These partnerships focus on raising awareness, enhancing education about the disease, and fostering a supportive community for patients and their families. The company works to advocate for policies that benefit patients and improve access to necessary treatments.
Conclusion:
Overall, Acadia Pharmaceuticals Inc. is at the forefront of biopharmaceutical innovation, particularly in the treatment of central nervous system disorders. With NUPLAZID leading the way in therapeutic advancements for Parkinsons Disease Psychosis, the company remains committed to ongoing research and development efforts. By fostering a strong emphasis on commercial success, patient support, education, and advocacy, Acadia Pharmaceuticals is positioned to make a significant impact in the lives of individuals affected by CNS disorders.
Segments:
1. Commercialization:
This segment is critical to the companys operations, as it encompasses all sales and marketing activities, including the promotion and distribution of Acadias flagship product, NUPLAZID. The commercialization team is responsible for building relationships with healthcare providers, payers, and patients to ensure that NUPLAZID is accessible to those in need. The team also manages ongoing marketing efforts and promotional campaigns to raise awareness of the product and educate stakeholders on its benefits.
2. Research and Development (R&D):
The R&D segment is a cornerstone of Acadia Pharmaceuticals’ mission. This segment is devoted to the comprehensive investigation and development of new therapies that target specific neurological and psychiatric disorders. The R&D team employs state-of-the-art techniques and methodologies to explore novel drug candidates, conduct preclinical studies, and execute clinical trials. Their research aims to understand the underlying mechanisms of various CNS disorders, allowing for the development of innovative treatments that provide relief to patients.
Products:
1. NUPLAZID:
NUPLAZID (pimavanserin) stands as Acadias flagship product and the first FDA-approved treatment specifically for Parkinson’s Disease Psychosis (PDP), receiving approval in April 2016. NUPLAZID is a selective serotonin inverse agonist that predominantly targets the 5-HT2A receptors in the brain, contributing to a significant reduction in hallucinations and delusions associated with PDP. The drug is noted for its efficacy and has undergone rigorous clinical trials that demonstrated its safety profile and effectiveness in managing symptoms of psychosis without exacerbating motor symptoms of Parkinsons disease.
Services:
1. Patient Support:
Acadia Pharmaceuticals offers extensive patient support services designed to assist individuals diagnosed with Parkinson’s Disease Psychosis. The patient support team provides educational resources, tools, and counseling to help patients effectively manage their condition. They also offer guidance on the correct administration of NUPLAZID to enhance compliance and ensure optimum therapeutic outcomes.
2. Educational Programs:
The company is committed to enhancing public and professional understanding of CNS disorders through a range of educational programs. These initiatives aim to increase awareness of Parkinson’s Disease Psychosis and its impact, covering the importance of proper diagnosis, treatment options, and support mechanisms available for patients and caregivers.
3. Medical Information:
Acadia Pharmaceuticals maintains a robust medical information service that is available to address inquiries regarding NUPLAZID and other therapeutic options. This service is designed to provide healthcare professionals and patients with timely and scientifically accurate information, helping them make informed decisions related to treatment.
4. Patient Advocacy:
Acadia Pharmaceuticals actively collaborates with patient advocacy organizations to support those living with Parkinson’s Disease Psychosis. These partnerships focus on raising awareness, enhancing education about the disease, and fostering a supportive community for patients and their families. The company works to advocate for policies that benefit patients and improve access to necessary treatments.
Conclusion:
Overall, Acadia Pharmaceuticals Inc. is at the forefront of biopharmaceutical innovation, particularly in the treatment of central nervous system disorders. With NUPLAZID leading the way in therapeutic advancements for Parkinsons Disease Psychosis, the company remains committed to ongoing research and development efforts. By fostering a strong emphasis on commercial success, patient support, education, and advocacy, Acadia Pharmaceuticals is positioned to make a significant impact in the lives of individuals affected by CNS disorders.